Vaxart Inc
Change company Symbol lookup
Select an option...
VXRT Vaxart Inc
BAC Bank of America Corp
XLF Financial Select Sector SPDR® Fund
FRAN Francesca's Holdings Corp
ED Consolidated Edison Inc
BIIB Biogen Inc
CNF CNFinance Holdings Ltd
LVS Las Vegas Sands Corp
AZDDQ Azure Dynamics Corp
$DWACSMN Dorsey Wright Country Stock NTRIndex
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Closing Price
$7.37
Day's Change
-0.63 (-7.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.15
Day's Low
7.10
Volume
(Light)
Volume:
17,873,785

10-day average volume:
56,891,537
17,873,785

Company Profile

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
74.32x
Price/Book (MRQ)
16.96x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

June 2020
Current Month
4.1M
Previous Month
3.3M
Percent of Float
8.74%
Days to Cover
1.1543 Days

Share Information

VXRT is in a share class of common stock
Float
73.3M
Shares Outstanding
74.2M
Institutions Holding Shares
45
12.76%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Wouter W. LatourChmn.
  • Andrei FloroiuCEO
  • Margaret A EcherdCAO
  • Sean N TuckerCSO
  • David TaylorOther

Address

  • 385 Oyster Point Boulevard, Suite 9A
  • South San Francisco, CA 94080
  • Phone: (650) 550-3500
  • Fax: (650) 871-8580
  • https://vaxart.com/

Insider Trading

During the most recent quarter, 46M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.